The ERACE-PA Global Surveillance Program: Ceftolozane/tazobactam and Ceftazidime/avibactam in vitro Activity against a Global Collection of Carbapenem-resistant Pseudomonas aeruginosa
Published in
European Journal of Clinical Microbiology & Infectious Diseases, July 2021
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 July 2021.
All research outputs
#24,745,186
of 34,344,963 outputs
Outputs from European Journal of Clinical Microbiology & Infectious Diseases
#3,316
of 4,227 outputs
Outputs of similar age
#307,637
of 474,875 outputs
Outputs of similar age from European Journal of Clinical Microbiology & Infectious Diseases
#25
of 38 outputs
Altmetric has tracked 34,344,963 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,227 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one is in the 16th percentile – i.e., 16% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 474,875 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 38 others from the same source and published within six weeks on either side of this one. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
